After years of research and clinical testing, we have developed non-invasive, accurate blood tests for early detection of cancer. By making cancer prevention routine, we enable everyone to take control of their own health. The more people take our breakthrough blood tests, the more lives we can save. Life over cancer.
To achieve our mission of transforming how cancer is diagnosed and managed with globally affordable non-invasive tests for early cancer detection and management, we have built a team of experts across multiple disciplines, including circulating tumor cells, imaging, instrumentation, next generation sequencing, bio-informatics, software and oncology diagnostics commercialization.
Oncologist and Professor of Medicine at the University of California at Davis School of Medicine
Debu Tripathy, MD
Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
Ashish Nimgaonkar, MD
Assistant Professor of Medicine Johns Hopkins; Associate Medical Director CBID
Shai Friedland, MD
Chief of Gastroenterology & Hepatology, VA Palo Alto Health Care System, Stanford University
Heinz Josef Lenz, MD
Professor of Medicine and Preventive Medicine, GI; Keck School of Medicine, UCSC
Mark Pegram, MD
Oncologist and Professor, Stanford; Director, Breast Cancer Oncology Program, Women’s Cancer Center
Mahul Amin, MD
Chair, Dept. of Pathology, College of Medicine Univ. of Tennessee Health Science Center;
UTHSC Gerwin Chair for Cancer Research
Dave Lawrence, MD
Advisor, Artiman Ventures; Former CEO & Chairman, Kaiser Foundation Health Plan and Hospitals
Chief Executive Officer
In 2012, as an Entrepreneur in Residence at a leading Silicon Valley Venture Firm, Artiman Ventures, Atul Sharan co-founded CellMax Life, applying semiconductor industry principles to a proprietary Circulating Tumor Cell (CTC) bio-mimetic CMx platform to develop affordable, clinically proven blood-tests for Early Cancer Detection and Treatment. He was motivated to start CellMax as two members of his family have been diagnosed with cancer – one of them was diagnosed with breast cancer within two weeks of receiving a conclusively negative mammogram. Atul is a veteran of the high-tech industry with experience as an engineer, serial entrepreneur, CEO and angel investor. He specializes in identifying unmet market needs and matching them with early-stage technologies to achieve dramatically better results than prevailing standards. He has done that successfully multiple times: AutoESL (acquired by Xilinx); ClearShape Technologies (acquired by Cadence), Numerical Technologies (Nasdaq IPO; acquired by Synopsys); Ambit Design (acquired by Cadence). Atul holds a BS in Engineering from IIT-India; MS in Engineering from UH, Texas and an MBA from UC-Berkeley.
Rui Mei, PhD
Chief Scientific Officer & VP of R&D
As Chief Scientific Officer at CellMax Life, Dr Mei leads a global team of R&D scientists, CLIA and CAP laboratory professionals, bioinformaticians and software engineers. She is responsible for the development of CellMax Life’s multi-biomarker platforms, including the circulating tumor cell (CTC) CMxTM, Next Generation Sequencing “SMSEQ, Methylation and Protein expression platforms. Prior to joining CellMax Life, Dr Mei was Vice President of R&D and Genomic Service Operations, and part of the founding team at Centrillion Biosciences where she established their next-generation sequencing for services to pharmaceutical companies, researchers and physicians. At Affymetrix, a pioneer in multi-biomarker analysis tools, Dr Mei led the development of multiple products for genotyping, re-sequencing, and gene expression analysis. She received her PhD in Biochemistry from the University of Michigan, Ann Arbor, and post-doctoral training in Nucleic Acid Enzymology at Stanford University. Dr Mei has published over 40 articles in peer-reviewed scientific journals and holds 20 patents.
Mana Javey, MD, PhD
Dr Javey is responsible for the regulatory approvals and accreditation of CellMax Life’s laboratories and is also responsible for Medical and Scientific Affairs. She is an authority on laboratory accreditation requirements for Circulating Tumor Cell technology. She led regulatory filings with the CMS (Centers for Medicare Services) and the College of America Pathologists which resulted in successful CLIA accreditation of the CellMax Life laboratory in Sunnyvale, California, and CAP accreditation of the company’s labs in both Taipei, Taiwan and Sunnyvale, California. Dr Javey holds MD, and PhD in immunology and biochemistry. She did her pathology residency training at University of California, San Francisco, and a postdoctoral fellowship at Stanford University, School of Medicine. She has won numerous institutional and national awards including the Dean’s Fellowship at Stanford and co-authored several peer-reviewed publications.
VP of Marketing and Business Development
At CellMax Life, Padma is responsible for worldwide marketing and business development. Padma has over 20 years of global life sciences strategy, marketing and product commercialization experience. Prior to CellMax, Padma led marketing for Guardant Health, including physician and patient education, and establishing product requirements for the company’s LDT and IVD tests, leading to a 100% increase in test volume and adoption by 60% of US medical oncologists. Prior to that, Padma led oncology product marketing at Ariosa (Roche Sequencing) where she defined product requirements, branding and launch plan for the “Avenio” liquid biopsy kits now successfully commercialized worldwide. Padma was head of oncology product marketing and business development for Affymetrix’s cancer portfolio including DNA, RNA and Protein expression products, including the “OncoScan” whole genome cancer profiling assay, which is available in 50 leading clinical laboratories and CROs worldwide. Padma began her career at McKinsey & Company as a consultant in the biopharmaceutical practice. She has an MBA-MPH from UC Berkeley and a Bachelors in Chemistry.
Bio Information In Progress
Please check back soon.
CellMax Life's mission is to transform how cancer is detected and managed with globally affordable non-invasive tests for early cancer detection and management. CellMax’s unique expertise in both Circulating Tumor Cell and Next Generation Sequencing of DNA and circulating tumor DNA (ctDNA) has enabled multiple highly effective precision medicine solutions for healthy people as well as patients diagnosed with cancer.
1271 Oakmead Parkway
Sunnyvale, CA 94085
Phone: +1 650-564-3905
18F-1 Park Street
Nangkang, Taipei City
(+886) 0800-555-885 (Taiwan)